OKYO Pharma Announces Executive Presentations at Eyecelerator and ARVO 2026 Meetings

On April 29, 2026, OKYO Pharma Limited announced that its leadership team will present at two upcoming scientific conferences in May 2026. CEO Robert J. Dempsey will present at Eyecelerator on May 1, focusing on addressing unmet needs in corneal and anterior segment diseases. Additionally, Chief Scientific Officer Raj Patil, PhD, will present a poster at the ARVO Annual Meeting on May 5, 2026. This presentation will detail first-in-human study results for Urcosimod (formerly OK-101) in treating neuropathic corneal pain (NCP), highlighting clinically meaningful pain reduction and quality-of-life improvements. Urcosimod is a lipid-conjugated chemerin peptide agonist and the first investigational therapy to receive an IND specifically for NCP, currently holding FDA Fast Track designation. The company recently completed a Phase 2 trial in NCP patients showing statistical significance in multiple endpoints and plans to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026. NCP is a debilitating condition with no current FDA-approved therapies.